On Tuesday, Following Stocks were among the “Top Losers” In U.S. Stock Exchange: Groupon, (NASDAQ:GRPN), Novo Nordisk, (NYSE:NVO), Marvell Technology Group, (NASDAQ:MRVL), Gilead Sciences, (NASDAQ:GILD)
Groupon Inc (NASDAQ:GRPN)’s shares dwindled -2.96%, and closed at $7.21. The stock has the beta value of 1.01, and its volatility for the week is 3.00%, while for the month it is 2.71%. The company has the market capitalization of $4.87B. The company holds the book value per share of 1.14, whereas cash per share is 1.59. Price to book ratio remained 6.32, while price to sale ratio is 1.53. Analysts mean recommendation for the stock is said to be 2.40 (where 1=Buy, 5=sale).
Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount worldwide. It also offers deals on products for which it acts as the merchant of record. The company offers deals in various categories, counting food and drink, events and activities, beauty and spa, health and fitness, home and garden, and automotive; deals on various product lines comprising electronics, sporting goods, jewelry, toys, household items, and apparel; features travel offers comprising hotels, airfare, and package deals; and tools, such as payments and credit card payment processing service, in addition to point-of-sale solutions to merchants.
Novo Nordisk A/S (ADR) (NYSE:NVO), declined -2.36%, and closed at $53.39. The company has the market capitalization of $116.05B. The beta value of the stock is 1.03. On the other hand the stock’s volatility for the week is 3.60%, and for the month is 1.92%. The stock’s price to book ratio is 25.92, however price to sale ratio is 9.01. Analyst’s mean recommendation regarding this stock is 2.00. (where 1=Buy, 5=Sale).
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, in addition to other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy.
Marvell Technology Group Ltd (NASDAQ:MRVL), dipped -3.16%, and closed at $14.70. The stock has price to sale ratio of 2.00, however, price to book ratio is 1.50. With recent decline, the year-to-date (YTD) performance reflected a 1.73% incline above last year. During the past month the stocks lose -10.09%, bringing three-month performance to 2.94% and six-month performance to 9.05%. The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).
Marvell Technology Group Ltd. designs, develops, and markets analog, mixed-signal, digital signal processing, and embedded and standalone integrated circuits. It offers mobile and wireless products comprising communications and applications processors; thin modems; and connectivity solutions, counting Wi-Fi, Bluetooth, near field communication, and FM; and mobile computing products, in addition to silicon solutions and Kinoma software. The company also provides a range of data storage products, such as hard disk drive and solid-state drive controllers.
Gilead Sciences, Inc (NASDAQ:GILD), dropped -2.54%, and closed at $98.13. The stock volatility for the week is 2.41%, while for the month remained 2.01%. The company holds consensus target price of $119.08.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 7.37 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 306.10% and Annual EPS growth for the past 5 years is considered as 39.10%.
The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
